Clinical applications and safety evaluation of the new CD19 specific T-cell engager antibody construct blinatumomab
Sign Up to like & getrecommendations! Published in 2017 at "Expert Opinion on Drug Safety"
DOI: 10.1080/14740338.2017.1338270
Abstract: ABSTRACT Introduction: Blinatumomab is a T-cell engager antibody construct with dual specificity for CD19 and CD3, inducing serial lysis of CD19 positive B cells by redirecting cytotoxic T cells. It has been approved for the… read more here.
Keywords: cd19; cell engager; antibody construct; blinatumomab ... See more keywords